Epigenetic therapeutics in autoimmune disease

Area of Science:

• Immunology
• Epigenetics
• Pharmacology

Background:

• Autoimmune diseases, such as lupus, are linked to epigenetic alterations.
• Global DNA hypomethylation is a significant epigenetic finding in lupus.
• Epigenetic changes are potentially reversible, making them attractive therapeutic targets.

Purpose of the Study:

• To explore the role of epigenetic modifications in autoimmune diseases.
• To identify novel therapeutic targets for autoimmune conditions.
• To evaluate DNA demethylation inhibitors as a potential treatment strategy for lupus.

Main Methods:

• Review of evidence linking epigenetic processes to autoimmune disease.
• Analysis of DNA methylation patterns in lupus.
• Identification of potential drug targets, including DNA methylating/demethylating enzymes and histone modification pathways.

Main Results:

• Global DNA hypomethylation is a prominent feature in lupus.
• Histone deacetylase (HDAC) inhibitors are advanced in clinical development.
• DNA demethylation inhibitors are proposed as a more suitable target class for lupus, with MBD2 identified as a candidate target in T cells.

Conclusions:

• Epigenetic dysregulation, specifically DNA hypomethylation, is implicated in lupus pathogenesis.
• Targeting DNA demethylation pathways, such as MBD2, presents a promising, albeit early-stage, therapeutic strategy for autoimmune diseases.